Ultrasound bone mass in schizophrenic patients on antipsychotic therapy

Human Psychopharmacology

Volumn 24, Issue 1, 2009, Pages 49-54

  Rey Sánchez, Purificación ^a   Lavado García, Jesús M ^a   Canal Macías, María L ^a   Gómez Zubeldia, María ^a   Roncero Martín, Raúl ^a   Pedrera Zamorano, Juan D ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

Antipsychotic drugs; Bone mass; Parathyroid hormone; Phalangeal bone ultrasound; Prolactin; Vitamin D

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; ATYPICAL ANTIPSYCHOTIC AGENT; CALCIFEDIOL; NEUROLEPTIC AGENT; PARATHYROID HORMONE; PROLACTIN; 25 HYDROXYVITAMIN D; 25-HYDROXYVITAMIN D; ACID PHOSPHATASE; DRUG DERIVATIVE; ISOENZYME; TARTRATE-RESISTANT ACID PHOSPHATASE; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE MASS; BONE RADIOGRAPHY; BONE TURNOVER; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; HUMAN; INSTITUTIONAL CARE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHALANX; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SCHIZOPHRENIA; SEX DIFFERENCE; SIDE EFFECT; VITAMIN BLOOD LEVEL; AGED; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; FINGER PHALANX; METABOLISM; MIDDLE AGED;

ACID PHOSPHATASE; ADULT; AGED; ALKALINE PHOSPHATASE; ANTIPSYCHOTIC AGENTS; BONE DENSITY; CONTROLLED CLINICAL TRIALS AS TOPIC; FEMALE; FINGER PHALANGES; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; PARATHYROID HORMONE; PROLACTIN; SCHIZOPHRENIA; SEX FACTORS; VITAMIN D;

EID: 60549101890     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.984     Document Type: Article

References (31)

1. Bainbridge KE, Sowers M, Lin X, Harlow SD. 2004. Risk factors for low bone mineral density and the 6 year rate of bone loss among premenopausal and perimenopausal women. Osteoporos Int 15(6): 439-446.
2. Benitez CL, Schneider DL, Barrett-Connor E, Sartoris DJ. 2000. Hand ultrasound for osteoporosis screening in postmenopausal women. Osteoporos Int 11(3): 203-210.
3. Carnevale V, Manfredi G, Romagnoli E, et al. 2004. Vitamin D status in female patients with primary hyperparathyroidism: does it play a role in skeletal damage? Clin Endocrinol (Oxf) 60: 81-86.
4. Cormier C. 2006. Parathyroid hormone in osteoporosis. Presse Med 35: 495-501.
5. Damilakis J, Papadokostakis G, Vrahoriti H. 2003. Ultrasound velocity through the cortex of phalanges, radius, and tibia in normal and osteoporotic postmenopausal women using a new multisite quantitative ultrasound device. Invest Radiol 38(4): 207-211.
6. Descos L, Andre C, Beorghia S, Vincent C, Revillard JP. 1979. Serum levels of b2-microglobulin - a new marker of activity in Crohn's disease. N. Engl J Med 301: 440-441.
7. Durosier C, Hans D, Krieg MA, et al. 2007. Combining clinical factors and quantitative ultrasound improves the detection of women both at low and high risk for hip fracture. Osteoporos Int 18(12): 1651-1659.
8. Gemalmaz A, Discigil G, Sensoy N, Basak O. 2007. Identifying osteoporosis in a primary care setting with quantitative ultrasound: relationship to anthropometric and lifestyle factors. J. Bone Miner Metab 25(3): 184-192.
9. Haddad PM, Wieck A. 2004. Antipsychotic-induced hyperprolactinemia: mechanisms, clinical features and management. Drugs 64(20): 2291-2314.
10. Halbreich U, Kinon BJ, Gilmore JA, Kahn LS. 2003. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 28 (Suppl 1): 53-67.
11. Henderson DC, Goff DC, Connolly CE, Borba CP, Hayden D. 2001. Risperidone added to clozapine: impact on serum prolactin levels. J. Clin Psychiatry 62(8): 605-608.
12. Howard L, Kirkwood G, Leese M. 2007. Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry 190: 129-134.
13. Howes OD, Wheeler MJ, Meaney AM, et al. 2005. Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment. J. Clin Psychopharmacol 25(3): 259-261.
14. Jung DU, Conley RR, Kelly DL, et al. 2006. Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study. J. Clin Psychiatry 67(9): 1391-1396.
15. Kishimoto T, Watanabe K, Takeuchi H, et al. 2005. Bone mineral density measurement in female inpatients with schizophrenia. Schizophr Res 77(1): 113-115.
16. Kudlacek S, Schneider B, Peterlik M, et al. 2003. Assessment of vitamin D and calcium status in healthy adult Austrians. Eur J Clin Invest 33: 323-331.
17. Kurzthaler I, Fleischhacker WW. 2001. The clinical implications of weight gain in schizophrenia. J. Clin Psychiatry 62 (suppl 7): 32-37.
18. Lean M, De Smedt G. 2004. Schizophrenia and osteoporosis. Int Clin Psychopharmacol 19(1): 31-35.
19. Lindsay R, Cosman F. 2001. Osteoporosis. In Harrison's Principles of Internal Medicine, 15th edn, Braunwald E, Fauci AS, Isselbacher KJ (eds). McGraw-Hill: New York; (Chapter 342).
20. Meaney AM, Smith S, Howes OD, O'Brien M, Murray RM, O'Keane V. 2004. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 184: 503-508.
21. Misra M, Papakostas GI, Klibanski A. 2004. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J. Clin Psychiatry 65(12): 1607-1618.
22. Need AG. 2006. Bone resorption markers in vitamin D insufficiency. Clin Chim Acta 368: 48-52.
23. Parfitt AM. 1969. Chlorothiazide induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism. N. Engl J Med 281: 5-59.
24. Pedrera JD, Canal ML, Carvajal J, et al. 2000. Influence of vitamin D administration on bone ultrasound measurements in patients on anticonvulsant therapy. Eur J Clin Invest 30: 895-899.
25. Rico H, Villa LF. 1993. Serum tartrate-resistant acid phosphatase as a biochemical marker of bone remodelling. Calcif Tissue Int 52: 149-150.
26. Scharla SH. 1998. Prevalence of subclinical vitamin D deficiency in different European countries. Osteoporos Int 8 (Suppl 2): 7-12.
27. Schneider B, Weber B, Frensch A, Stein J, Fritze J. 2000. Vitamin D in schizophrenia, major depression and alcoholism. J. Neural Transm 107: 839-842.
28. Ventura V, Mauloni M, Mura M, Paltrinieri F, de Aloysio D. 1996. Ultrasound velocity changes at the proximal phalanxes of the hand in pre-, peri- and postmenopausal women. Osteoporos Int 6(5): 368-375.
29. von Muhlen DG, Greendale GA, Garland CF, Wan L, Barret-Connor E. 2005. Vitamin D, parathyroid hormone levels and bone mineral density in community-dwelling older women: the Rancho Bernardo Study. Osteoporos Int 16(12): 1721-1726.
30. Wüster C, Hadji P. 2001. Use of quantitative ultrasound densitometry (QUS) in male osteoporosis. Calcif Tissue Int 69(4): 225-228.
31. Yilmazi M, Keles I, Aydin G, et al. 2005. Plasma leptin concentrations in postmenopausal women with osteoporosis. Endocr Res 31(2): 133-138.